Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.

PURPOSE The purpose of this study is to evaluate the usefulness of serum DNA methylation of five tumor suppressor genes for early detection of lung cancer. EXPERIMENTAL DESIGN Methylation status in serum DNA from 200 patients undergoing bronchofiberscopic examination for abnormal findings on chest radiograph detected by lung cancer screening or surveillance was examined using methylation-specific PCR. RESULTS Ninety-one patients were given a pathologic diagnosis of lung cancer, 9 other malignant diseases, and 100 nonmalignant pulmonary diseases. In patients with lung cancer, methylation was detected in 18.7% for MGMT, 15.4% for p16(INK4a), 12.1% for RASSF1A, 11.0% for DAPK, and 6.6% for RAR-beta, which was higher compared with that in patients with nonmalignant diseases. Age and smoking status seemed to associate with methylation status. Sensitivity, specificity, and predictive value of methylation in at least one gene for diagnosis of lung cancer were 49.5%, 85.0%, and 75.0%, respectively. Adjusted odds ratio (95% confidence interval) for having lung cancer was 5.28 (2.39-11.7) for patients with methylation in one gene and 5.89 (1.53-22.7) for those with methylation in two or more genes. It is of note that methylation was identified in 50.9% of stage I lung cancer patients, whereas serum protein tumor markers were positive in 11.3% of them. CONCLUSIONS These results suggest that identification of promoter methylation of tumor suppressor genes in serum DNA could be useful for early detection of lung cancer.

[1]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.

[2]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[3]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[4]  Robert A. Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2003 , 2003, CA: a cancer journal for clinicians.

[5]  B. Levin,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[6]  W F Taylor,et al.  Lung cancer screening: the Mayo program. , 1986, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[7]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[8]  Feng Li,et al.  Mass screening for lung cancer with mobile spiral computed tomography scanner , 1998, The Lancet.

[9]  J. Herman,et al.  Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. , 1999, Blood.

[10]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[11]  Calum MacAulay,et al.  Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions , 2002, Oncogene.

[12]  S. Goodman,et al.  Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  P C Prorok,et al.  Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. , 2000, Journal of the National Cancer Institute.

[14]  D. Ihde,et al.  Chemotherapy of Lung Cancer , 1992 .

[15]  A. Kurt,et al.  Microsatellite alterations in plasma DNA of small cell lung cancer patients , 1996, Nature Medicine.

[16]  M. Farthing,et al.  A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  T. Nakajima,et al.  Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non‐small cell lung cancers , 1998, International journal of cancer.

[18]  J. Mulshine.  Screening for lung cancer: in pursuit of pre-metastatic disease , 2003, Nature Reviews Cancer.

[19]  Diane D. Liu,et al.  Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. , 2002, Cancer research.

[20]  Melvyn S. Tockman,et al.  Survival and Mortality from Lung Cancer in a Screened Population: The Johns Hopkins Study , 1986 .

[21]  C. Carpenter,et al.  DNA methylation analysis: a powerful new tool for lung cancer diagnosis , 2002, Oncogene.

[22]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[23]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[24]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Pfeifer,et al.  The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas , 2001, Oncogene.

[26]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[27]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[28]  John K. Wiencke,et al.  p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer , 2001 .

[29]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[30]  J. Minna,et al.  Aberrant DNA methylation in lung cancer: biological and clinical implications. , 2002, The oncologist.

[31]  Ling Li,et al.  Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. , 2002, Cancer letters.

[32]  A. Kraus,et al.  Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[34]  S. Groshen,et al.  Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  David Sidransky,et al.  Microsatellite alterations in serum DNA of head and neck cancer patients , 1996, Nature Medicine.

[36]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Kiura,et al.  A case-control study of lung cancer screening in Okayama Prefecture, Japan. , 2000, Lung cancer.

[38]  E. Mark,et al.  p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. , 2001, Cancer research.

[39]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[40]  B J Flehinger,et al.  Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. , 1984, Chest.

[41]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[42]  Patrick C. Walsh,et al.  American Cancer Society guidelines for the early detection of cancer. , 2002, CA: a cancer journal for clinicians.

[43]  B. Shapiro,et al.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.

[44]  S. Swensen,et al.  Screening for lung cancer with low-dose spiral computed tomography. , 2000, American journal of respiratory and critical care medicine.

[45]  H. Miyamoto.  Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. , 1986, Acta medica Okayama.

[46]  J. Jen,et al.  Molecular detection of genetic alterations in the serum of colorectal cancer patients. , 1998, Cancer research.

[47]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[48]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[49]  C. Henschke.  Early lung cancer action project , 2000, Cancer.

[50]  R. Dodge.  Sensitivity of methacholine testing in occupational asthma. , 1986, Chest.

[51]  F. Khuri,et al.  Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[52]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.